SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Chemical Name: 2-((2R,3R,5S)-6-((1S,3S,5Z,7R,10S,11R,12S,13E)-7-Allyl-10-hydroxy-14-((1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methoxy-3,5,11,13-tetramethyl-8-oxo-12-(((S)-piperidine-2-carbonyl)oxy)tetradeca-5,13-dien-1-yl)-2-hydroxy-5-methoxy-3-methyltetrahydro-2H-pyran-2-yl)-2-oxoacetic acid
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Smiles: OC(C([C@]1(O)OC([C@@H](OC)C[C@@H](C)C/C(C)=C\[C@@H](CC=C)C(C[C@H](O)[C@@H](C)[C@@H](/C(C)=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)OC([C@@]3([H])NCCCC3)=O)=O)[C@@H](OC)C[C@H]1C)=O)=O
Tacrolimus 21-Carboxylic Acid Impurity is chemically 2-((2R,3R,5S)-6-((1S,3S,5Z,7R,10S,11R,12S,13E)-7-Allyl-10-hydroxy-14-((1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methoxy-3,5,11,13-tetramethyl-8-oxo-12-(((S)-piperidine-2-carbonyl)oxy)tetradeca-5,13-dien-1-yl)-2-hydroxy-5-methoxy-3-methyltetrahydro-2H-pyran-2-yl)-2-oxoacetic acid. Tacrolimus 21-Carboxylic Acid Impurity is supplied with detailed characterization data compliant with regulatory guideline. Tacrolimus 21-Carboxylic Acid Impurity can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Tacrolimus.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Development and validation of a stability indicating HPLC assay method for tacrolimus in semi-solid dosage form & bulk drug
By Gejage, Santosh; Amin, Purnima
From Indo American Journal of Pharmaceutical Research (2018), 8(5), 1097-1106